TRAIL在膀胱移行细胞癌的表达与预后关系

目的检测膀胱移行细胞癌(BTCC)和正常膀胱组织中肿瘤坏死因子相关凋亡诱导配体（TRAIL）的表达,探讨TRAIL表达与BTCC预后的关系。方法免疫组化Elivision法检测76例BTCC和15例正常膀胱组织病理标本中TRAIL的表达;结合临床病理学资料分析其之间的相关性。结果76例BTCC病理标本中有45例(59.21%)TRAIL阴性表达,G2、G3组的TRAIL阴性表达率(68.63%)明显高于G1组(40.00%, P＜0.05)；肿瘤多发组中TRAIL阴性表达率(75.86%)明显高于单发组(48.94%, P＜0.05)。log rank test分析TRAIL表达阴性组与阳性组间无复发生存率有统计学意义(P＜0.05),TRAIL阴性表达组的无复发生存时间(33.65月)明显低于阳性表达组(46.49月)。结论TRAIL在BTCC中表达下调,且与BTCC数目、分级、复发相关,可作为判断BTCC预后的参考指标。

Correlation of TRAIL expression with prognosis of bladder transitional cell carcinoma

Objective To determine expression of tumor necrosis factor-related apoptosis-inducing ligand(TRAIL) in bladder transitional cell carcinoma(BTCC) and normal bladder tissues and to explore the correlation among TRAIL and clinico-pathological parameters and prognosis of BTCC.Methods TRAIL protein expression was determined by immunohistochemistry assay(Elivision).Results TRAIL negative expression was shown in 45(59.21%) of the 76 cases of BTCC,and it was higher in poorly differentiated(G2,G3) tumors than in wel...